Working… Menu

Effectiveness of PENTABIOCEL in Clinical and Laboratory Recovery of Children With Celiac Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03857360
Recruitment Status : Recruiting
First Posted : February 28, 2019
Last Update Posted : March 25, 2020
Noos S.r.l.
Information provided by (Responsible Party):
Carlo Catassi, M.D., Università Politecnica delle Marche

Brief Summary:
Celiac disease (CD) is an inflammatory condition of the small intestine. Environmental and genetic factors are involved in the development of CD. Apart from environmental and genetic factors other factors may also be involved, such as alteration in intestinal microbiota. Probiotic supplementation has been shown to be able to determine the intestinal healing. Recently the use of a mixture of some specific bacterial strains has shown its effectiveness. In this study effectiveness of a probiotic "Pentabiocel" which is a mixture of five different bacterial strains will be evaluated in CD affected children (already on a gluten-free diet) through a double-blind randomised placebo control trial.

Condition or disease Intervention/treatment Phase
Celiac Disease Dietary Supplement: Pentabiocel Dietary Supplement: Placebo Not Applicable

Detailed Description:

Celiac disease (CD) is an intestinal inflammatory condition characterized by permanent intolerance to gluten, a protein complex present in wheat, barley, and rye, in genetically predisposed subjects. In the early phase of the disease, specific autoantibodies are generally present, which is relevant for diagnostic purposes (especially anti-tissue transglutaminase antibodies (anti TTG) of IgA (immunoglobulin A) class and anti-endomysial antibodies( EMA), and a duodenal and jejunal mucosal lesion that is characterized by an increase in intraepithelial lymphocytes (IEL), hypertrophy of crypts and villous atrophy. The only accepted and effective treatment for CD so far is a lifelong strict gluten-free diet(GFD).

On the clinical level, CD can have an extremely variable expression, from almost silent forms to cases with more or less striking intestinal and extra-intestinal manifestations. Treatment with a strict GFD causes gradual normalisation of the intestinal lesion (generally within 12-24 months). The persistence of a minimal intestinal lesion and of mostly gastro-enteric symptoms, is not rare in adulthood, especially for the difficulty of maintaining a "zero gluten content" diet over time. The "timing" of recovery induced by the GFD is variable from patient to patient and depends on numerous factors such as presentation mode (typical, atypical or silent), the age of onset, adherence to a strict GFD, etc. Among the factors that may condition the normalisation of the clinical picture. According to some recent data, the quantitative and qualitative typology of the intestinal microbiome may have role. Prospective studies in healthy infants who are at risk of developing CD have shown that the Human Leukocyte Antigen (HLA) genotype, together with other environmental factors, influences the composition of the microbiota. In addition, celiac patients have alterations of the intestinal microbiome (dysbiosis) that do not completely normalize even after starting GFD. It has therefore been suggested that CD may favor dysbiosis which in turn negatively influences intestinal mucosal damage and can promote inflammation through the expansion of harmful bacteria and the reduction of beneficial bacteria.

Probiotics are live microorganisms, that when ingested in appropriate quantities, give to the host benefits. Some probiotics may digest gluten and are thus able to reduce their toxicity when used in fermentation processes. For example, a research group (Di Cagno et al.) has shown that bakery products made using a natural yeast with wheat flour fermented by proteases of lactobacilli and mushrooms, can be taken with confidence by celiac patients. This data suggests that the simple administration of a probiotic is capable to provide benefit in patients with CD leading to an improvement also of intestinal symptoms. However, it is clear from the literature that not all probiotic strains possess this characteristic. It has been shown that a mixture of probiotic strains, in particular belonging to the species Lactobacillus paracasei, Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium animalis subsp lactis, is able to significantly improve the irritable colon-like gastrointestinal symptoms of patients with CD. Pentabiocel is the trade name of the product containing the above mentioned probiotic mixture: Lactobacillus paracasei (LMG P-17504), Lactobacillus plantarum (CECT 4528), Bifidobacterium breve Bbr8 (LMG P-17501), Bifidobacterium breve (BL10 LMG P-17500) and Bifidobacterium animalis subsp lactis Bi1 (LMG P -17,502).

In this randomized double blind placebo controlled trial study investigators will investigate the effect of "Pentabiocel" on children already on GFD.

The aim of this study is to evaluate the efficacy of "Pentabiocel" in the clinical and laboratory recovery of children with celiac disease

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effectiveness of PENTABIOCEL in Clinical and Laboratory Recovery of Children With Celiac Disease: A Randomized Double Blind Placebo Controlled Trial
Actual Study Start Date : March 15, 2019
Estimated Primary Completion Date : March 15, 2021
Estimated Study Completion Date : March 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Celiac Disease

Arm Intervention/treatment
Active Comparator: Pentabiocel
Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
Dietary Supplement: Pentabiocel
Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.

Placebo Comparator: Placebo
Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
Dietary Supplement: Placebo
Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.

Primary Outcome Measures :
  1. Assessment of recovery time of clinical features [ Time Frame: 3 months ]
    After three months of probiotic treatment patients will be compared with their clinical symptoms evaluating score based Celiac symptom Index (CSI) developed by Leffler DA et al.

Secondary Outcome Measures :
  1. Differences between two treatment groups related to all the evaluated parameters [ Time Frame: 3 & 6 months ]

    Differences between the two treatment groups (Placebo and control )related to all the parameters evaluated and in particular: (a) Weight (in kilograms) , height (in meter) will be combined to measure BMI (at the time of enrolment and after follow up 3 and 6 months).

    (b) Anti tissue transglutaminase IgA serology level in cubic inch ( CU) (at the time of enrolment and after follow up 3 and 6 months).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children / adolescents aged between 2 and 16 recruited at the time of diagnosis of celiac disease.

The diagnosis of celiac disease will be performed according to the ESPGHAN 2012 Guidelines.

Exclusion Criteria:

  • Patients with autoimmune comorbidity (eg type 1 diabetes) or other associated chronic diseases
  • Associated serum IgA selective deficiency
  • Poor adherence to gluten free diet at the 6-month control, measured by a score> 10 at the Wessels questionnaire.
  • Adherence to the intervention protocol <85%.
  • Antibiotic therapy performed during the 7 days preceding T0 and / or T6.
  • Antibiotic therapy during the 3 months of probiotic / placebo treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03857360

Layout table for location contacts
Contact: Carlo Catassi, MPH +39 071 596 23 64
Contact: Elena Lionetti, PhD +39 071 596 23 64

Layout table for location information
Department of Pediatrics, via Corridoni 11 Recruiting
Ancona, Italy, 60123
Principal Investigator: Carlo Catassi, MD         
Sponsors and Collaborators
Università Politecnica delle Marche
Noos S.r.l.
Layout table for investigator information
Principal Investigator: Carlo Catassi, MPH Univeristà Politecnica delle Marche, Ancona, Italy
Principal Investigator: Elena Lionett, PhD Univeristà Politecnica delle Marche, Ancona, Italy
Principal Investigator: Basilio Malamisura Cava de' Tirreni - Ospedale di cava De' tirreni, UO di Pediatria, Salerno, Italy
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Carlo Catassi, M.D., Professor and Head, Department of Pediatrics, Università Politecnica delle Marche Identifier: NCT03857360    
Other Study ID Numbers: CD-PENTABIOCEL
First Posted: February 28, 2019    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Carlo Catassi, M.D., Università Politecnica delle Marche:
Additional relevant MeSH terms:
Layout table for MeSH terms
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases